Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

344.42 -1.31 (-0.38%)

Streaming Delayed Price Updated: 11:45 AM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

66 67 Next >

Stocks Struggle As U.S. Dollar Sees Safety Bid ↗

January 16, 2024

Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Why Vera Therapeutics Stock Soared by 22% This Week ↗

January 12, 2024

Executive changes and a bullish analyst take combined to boost sentiment on the company.

Via The Motley Fool

Why NASDAQ:AMGN is a Top Pick for Dividend Investors. ↗

January 12, 2024

Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN).

Via Chartmill

How Is The Market Feeling About Amgen? ↗

January 10, 2024

Via Benzinga

Looking At Amgen's Recent Unusual Options Activity ↗

January 09, 2024

Via Benzinga

Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors ↗

January 08, 2024

Via Benzinga

Looking At Amgen's Recent Unusual Options Activity ↗

January 05, 2024

Via Benzinga

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗

January 11, 2024

AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.

Via Benzinga

Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains ↗

January 10, 2024

Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed.

Via InvestorPlace

Topics Stocks

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

Via Investor Brand Network

Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning

January 02, 2024

Via Investor Brand Network

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END

Via FinancialNewsMedia

3 health care stocks off to strong starts in 2024

January 10, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

Via MarketBeat

Topics Artificial Intelligence

Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference ↗

January 10, 2024

Cramer shared his insights during his attendance at JPMorgan's healthcare conference,

Via Benzinga

Topics Artificial Intelligence

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

Via FinancialNewsMedia

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 08, 2024

Via Benzinga

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

From FN Media Group LLC

Via GlobeNewswire

A Rough Start To 2024 What Might Be In Store For The Rest Of 2024? ↗

January 07, 2024

The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year.

Via Talk Markets

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

January 04, 2024

Via Benzinga

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

Revenge of the Boring Stocks! Dividends Are Sexy Again. ↗

January 03, 2024

Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.

Via InvestorPlace

Did Santa Claus Claus Leave Town A Day Early? ↗

January 02, 2024

With the exception of the Dow, stocks are down hard to begin the new calendar year.

Via Talk Markets

Topics Stocks

Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024 ↗

January 02, 2024

Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields.

Via Benzinga

Topics Stocks

3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar ↗

January 01, 2024

I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.

Via The Motley Fool

Topics ETFs Retirement

Amgen Stock Sees Relative Strength Rating Improve To 74 ↗

December 29, 2023

Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.

Via Investor's Business Daily

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.